FDA Approves Omeros' Yartemlea as First Treatment for Rare Post-Transplant Blood Disorder TA-TMA
核心洞察
The FDA has approved Yartemlea (搜索) (narsoplimab-wuug (搜索)) as the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (搜索) (TA-TMA (搜索)), a rare and often fatal post-transplant complication.
In the pivotal study of 28 adult patients, 61% achieved complete response and 100-day survival reached 73%, with peer-reviewed studies showing a three- to fourfold reduction in mortality compared to external controls.
Yartemlea (搜索) represents the first drug to selectively inhibit the lectin pathway of complement by targeting MASP-2 (搜索), preserving immune functions while blocking disease-driving complement activation.
The U.S. Food and Drug Administration has approved Yartemlea (搜索) (narsoplimab-wuug (搜索)) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (搜索) (TA-TMA (搜索)), marking a significant breakthrough for patients facing this rare and often fatal post-transplant complication. The approval establishes Yartemlea as the first and only FDA-approved therapy for TA-TMA and represents the first drug to selectively inhibit the lectin pathway of the complement system.
Breakthrough Mechanism of Action
Yartemlea (搜索) targets MASP-2 (搜索), a key enzyme in the lectin pathway of complement activation, blocking disease-driving complement activation while preserving immune functions critical for host defense. This selective inhibition represents a novel therapeutic approach for TA-TMA (搜索), a life-threatening complication driven by endothelial injury and uncontrolled complement activation that leads to multi-organ dysfunction and high mortality following stem cell transplantation.
The therapy is approved for adults and children aged two years and older, addressing a critical unmet medical need across age groups affected by this devastating condition.
Clinical Evidence Supporting Approval
FDA approval was based on data from a single-arm study involving 28 adult patients, supplemented by supporting evidence from an expanded access program that included both adult and pediatric patients. In the pivotal study, 61% of patients achieved a complete response, while 100-day survival reached 73%. Notably, all treated patients were classified as high-risk with poor baseline prognosis.
The expanded access population demonstrated similar positive outcomes, reinforcing the therapy's efficacy across different patient groups. Peer-reviewed studies revealed that treatment with Yartemlea (搜索) was associated with a three- to fourfold reduction in mortality compared with external control cohorts.
Dramatic Survival Improvements
The clinical impact becomes particularly striking when examining patients who had failed prior off-label therapies. In this challenging population, one-year survival reached 50% with Yartemlea (搜索) treatment, significantly exceeding historical rates below 20%. This represents a substantial improvement in outcomes for patients with limited therapeutic options.
Commercial Launch Strategy
Omeros has positioned itself for a comprehensive market entry, planning to launch Yartemlea (搜索) in the U.S. in January 2026. The company has proactively established the necessary infrastructure, with billing and reimbursement codes already in place. This preparation includes assembling a commercial organization with a hematology-focused sales force and establishing reimbursement infrastructure, including a national ICD-10 diagnostic code for TA-TMA (搜索) and a CPT procedural code for narsoplimab.
Global Regulatory Timeline
While the U.S. approval represents a major milestone, Omeros continues to pursue international market access. A parallel marketing authorization application is under review by the European Medicines Agency (搜索), with a regulatory decision expected in mid-2026, potentially expanding access to this breakthrough therapy for patients worldwide.
Broader Pipeline Implications
The Yartemlea (搜索) approval validates Omeros' complement-focused strategy and its pipeline of late-stage monoclonal antibody programs targeting the lectin pathway. The company's second late-stage program, zaltenibart (OMS906), is a MASP-3 (搜索) inhibitor in Phase 2 development for paroxysmal nocturnal hemoglobinuria (搜索) and C3 glomerulopathy (搜索). In October 2025, Omeros entered into an asset purchase and license agreement with Novo Nordisk, granting exclusive global rights to zaltenibart and related assets for an upfront payment of $240 million, up to $2.1 billion in milestone payments, and tiered royalties on global net sales.